46 – cGMP Fundamentals and Regulatory Overview (S20E1)

ever stopped and thought about, you know, when
you grab some medicine from your cabinet, how
do you just know it's gonna do what it says and
that it's safe to take? That trust, that's what
we're gonna dig into today. We're talking about
current good manufacturing practices. CGMP. CGMP,
the foundation of making sure all those meds
and pills and everything are actually safe and
actually work. You bet. And you've pulled together
a really interesting collection of materials
for this. We're talking FDA regulations, guidelines,
the whole nine yards of how medicines are made.
So I guess our mission today is to break all
that down, right? To understand the core of CGMP
and all those regulations and really see how
they impact the quality and safety of the drugs
we all use. Absolutely. We'll be diving into
the Code of Federal Regulations. That's the 21
CFR. We'll touch on dietary supplements a bit.
That's part 111. But really, zoom in on part
211, the heart of it all, for finished pharmaceuticals.
And of course, we can't forget the global perspective.
We've got to bring in the International Council
for Harmonization, the ICH. Plus, we've got insights
from FDA training materials and what folks in
the industry are saying so we can get a complete
picture but, you know, one that doesn't make
your head spin. Yeah, for sure. By the end of
this deep dive, you'll really grasp those CGMP
fundamentals. You'll get why the FDA is so important
and understand the huge role of what we call
quality culture in making sure medicines are
made the right way. Okay, let's rewind a bit.
How did we even get to this whole GMP thing in
the first place? It wasn't like, you know, medicines
were always made to these high standards, right?
You're right. The very beginning, if you can
believe it, goes all the way back to 1906 here
in the US. we had the Pure Food and Drug Act.
That was huge, at least for its time, to ensure
food and drugs were pure, especially when they
were sold across state lines. It was like the
first baby step towards protecting consumers.
So that was like the initial spark then. Yeah,
you could say that. But the real push towards
the modern CGMP we know today, that came from
some pretty tragic situations. One that keeps
popping up in your sources, for instance, is
the sulfanilamide elixir disaster back in 1937.
It's a stark reminder of why we need CGMP. Oh
yeah, that was a terrible incident. A company
decided to use, get this, diethylene glycol,
to dissolve this drug, to make it a liquid. Problem
is, we know now that stuff is toxic, really toxic.
And the worst part? There were no rules back
then to even test if that new liquid form was
safe before people started taking it. Exactly.
Safety testing wasn't required by the regulations
at the time. It's a really sad story, but it
forced everyone to wake up and realize... Making
sure a drug was pure that wasn't enough. You
had to test it make sure it was safe before giving
it to people It's kind of wild to think how those
awful events from so long ago shaped how we make
safe medicines today. Yes Really makes you appreciate
what we have now. So Fast forward to today's
CGMP. What's like the big idea the core principle
behind it all? At its heart, it's quality by
design. Don't just check the final product. Make
sure every step, every part is made to a high
standard right from the start. Like if you're
building a car, you wouldn't just try to start
it at the end and hope it works right. You'd
make sure every single part from the engine to
the brakes is made to exact specifications so
you know it's going to run smoothly and safely.
Yeah, that makes sense. In pharmaceuticals, it
means we don't just test quality at the end.
We build it in every step of the way. That's
CGMP. It's proactive, preventing problems before
they even have a chance to pop up. Build it in,
not just test it out at the end. I like that.
Like when you're cooking, you can't just hope
the final dish tastes good. You gotta have the
right ingredients, and you gotta follow the recipe
carefully. Perfect analogy. And to do this right
in the pharmaceutical world, we need a deep understanding
of critical quality attributes, or CQAs. This
applies to both the raw drug substance and the
final drug product. CQAs. Can you give us an
example of what one of those would be? Sure.
Imagine you have a headache and take a pain reliever.
The CQA would be confirming it actually has the
correct amount of pain relieving ingredient in
each pill. Not more, not less. That's what assay
is all about. Okay, I see. So that's one example.
Then there's identity. Confirming it really is
the drug it says it is. No mix -ups, no substitutions.
Purity is another big one, ensuring there's no
contamination, no nasty stuff that shouldn't
be there. These are just the basics, the building
blocks. The Certified Pharmaceutical GMP Professional
Handbook goes into even more detail on this.
Depending on what the medication is, there might
be other CQAs that are really important. Like,
if it's something you inhale, particle size matters.
Or if it's an injection, well, it has to be sterile,
free of any bacteria. So basically you're carefully
controlling all these specific things throughout
the whole process to make sure the final product
is good. Now who's making sure all this happens?
Who's in charge of keeping everyone in line?
In the U .S. that's the FDA's job. the Food and
Drug Administration. They're the ones who set
the rules of the game for CGMP and then make
sure everyone's playing by those rules. Right.
The FDA. They're the referees making sure no
one's cutting corners. And those rules, they're
all laid out in the code of federal regulations,
the 21 CFR. Exactly. And within the 21 CFR, there
are a bunch of parts that are super relevant
to CGMP. You might be surprised to know that
GMP isn't just for pharmaceuticals. Parts 110
and 111, for example. They cover GMP for food
and dietary supplements. Wait, really? So those
protein powders and vitamins, they're made following
GMP, too? To some extent, yes. Now, the specific
rules are a bit different compared to pharmaceuticals.
But the main idea is the same. Clean facilities
and equipment, no contamination, proper control
of how things are made. You see this in the Interfarm
CRC Press Index for those parts of the CFR. The
EAS consulting group even has a whole video on
21 CFR111 for dietary supplements. Okay, interesting.
So it's a broader set of principles, but if we're
talking about the prescriptions and over -the
-counter meds we all use, Part 211, that's the
main one, right? That's the heart of it for pharmaceuticals.
Part 211 is broken down into subparts, and each
one dives deep into a key aspect of drug production.
Let's start with subpart C, which is all about
the buildings and facilities. Buildings and facilities
might sound simple, but I'm guessing it's a lot
more than just having a building, right? Oh yeah,
way more. This subpart is all about clean, sanitary
conditions. We're talking no pests like rodents
or insects. Imagine those in a place where they're
making medicines. Yuck. Then you've got proper
waste disposal, which is super important to prevent
any kind of contamination. Makes sense. You don't
want anything nasty getting into the medicines.
Right. And Section 211 .56 of the CFR and the
Bleasner Audit Guide, they both emphasize this.
But it's not just about cleanliness. It's also
about space. You need enough room to do everything
properly to prevent things from getting mixed
up, especially in the labs where they do all
the testing. Oh, yeah. I can imagine how cramped
conditions could lead to mistakes. Exactly. The
EAS Consulting Group talks about this in one
of their videos. They emphasize that even lab
areas need enough space so they can do all those
critical tests safely and accurately. OK, so
we've got clean, well -designed facilities with
enough space. What about the actual equipment
they use to make all those medicines? I'm guessing
that's where Subpart D comes in, right? That
covers equipment. You got it. Subpart D gets
really specific about how the equipment is designed,
how it's built, how it's maintained. And they're
big on cleaning, of course. but also on a really
important concept called qualification. Qualification.
That sounds pretty official. What does that involve?
It's basically a whole process to show with proof
that the equipment they're using can actually
do what it's supposed to do and that it does
it right consistently. Think of it like this.
You buy a brand new oven. You want to make sure
it works properly, right? Oh yeah, of course.
So first, you check if it's plugged in right
and everything's set up according to the instructions.
That's like installation qualification or IQ
in the pharma world. Okay. Then you test if it
heats up to the right temperatures, if the timer
works, all that. That would be like operational
qualification or OQ. I see. So it's not just
about having the equipment. It's about making
sure it actually works as intended. Exactly.
And then comes the real test. You bake a few
batches of your favorite cookies. If they come
out perfect every time, that shows your oven
can reliably do its job. That's like performance
qualification or PQ. The Milteni biotech video
and some stuff from our past seasons cover this
whole qualification thing really well. It's all
about proving the equipment is up to snuff. Okay,
IQ, OQ, PQ. Got it. It's like a triple check
system for the equipment. What else is in subpart
D? It's also all about calibration, making sure
those balances, thermometers, all those tools
are giving accurate readings. That comes up in
the EAS consulting group videos and also in one
of our past deep dives on good laboratory practices,
GLP. Calibration. Yeah, like tuning a guitar
to make sure it plays the right notes. OK, so
we've got the facilities, the equipment all checked
out. Now, what about the actual stuff that goes
into making the drugs, the raw materials and
all that? Where are the rules for those? Ah,
that's where subpart E steps in. control of components
and drug product containers and closures. This
one's all about strict procedures written down
and followed to the letter for everything from
when those materials arrive making sure they
are what they say they are all the way to how
they're stored and tested before they can be
used. So they can't just trust whatever the supplier
sends them. They've got to verify everything,
right? Absolutely. Every single batch of those
components, the containers, the closures, everything,
they've got to be tested carefully to make sure
they meet the quality standards. And it's the
quality control unit, the QC folks, who have
the final say on whether those materials are
good to go or not. OK, so QC, they're the gatekeepers
here. Makes sense. This is actually covered in
section 211 .84. of the CFR and that helpful
video on good documentation practices. Documentation
is key here, so QC can track everything. Now,
once they've got all those quality checked ingredients,
the next step is actually making the drug. That's
subpart F territory, right? Production and process
controls. Yeah, subpart F, the heart of the operation,
I guess. What's the focus there? This is where
those detailed written instructions for making
the drug really matter. Every single person involved
has to follow them precisely. And it's not just
about following steps. It's about checking along
the way. They call these in -process controls.
Oh, so like if they're mixing something, they're
checking the temperature, the pH, all that as
they go. Exactly. These in -process controls
are like checkpoints throughout the process,
making sure everything is going right and the
final product will meet all those quality standards.
Sounds like a lot of checking and double checking.
It is, but it's crucial, especially when we're
talking about things like preventing contamination,
which is a big deal for sterile products like
injections. And then there's process validation,
where they prove scientifically that the whole
manufacturing process, if done correctly, will
make a good quality product every time. Process
validation. That sounds complicated. Oh, it definitely
can be. There are whole guidelines and books
about it. One that comes to mind is Syed Intiaz
Haider's book, Pharmaceutical Master Validation
Plan. It just goes to show how important this
is. All right. So let's say they've made the
drug, followed all the procedures. Next step.
Gotta package it up, label it correctly. I guess
that's where so part G comes in. Packaging and
labeling control. You're right on track. This
part's all about keeping tight control over all
those materials, labels, packaging, everything.
It's about making sure the right label is used
for the right drug and strength, that the labels
are printed correctly, and even keeping track
of how many labels are printed and used just
to avoid any chance of a mix -up. Wow, label
mix -ups, that could be really bad. It could
be disastrous. Someone could end up taking the
wrong medicine or the wrong dose, all because
of a labeling error. So the regulations are super
strict here. They even require tamper -evident
packaging for over -the -counter drugs, you know,
like those seals you see on bottles. Yeah, yeah,
I know those. So those are there because of these
CGMP regulations. Exactly. All those details
are in sections 211 .122, 211 .125, and 211 .132
of the CFR. Okay, lots of regulations for that.
So the drug is made, it's packaged up, labeled
correctly. What happens next? Now it's time for
testing. Subpart Iborotory Controls. This is
where they make sure the final product actually
meets all those quality standards. Ah, the quality
check at the end. Not just at the end. They do
testing all along the way. But this subpart lays
out the requirements for the labs themselves.
They need the right facilities, they need to
use scientifically sound methods for testing,
and they need qualified people doing the testing.
It makes sense, but where do those testing methods
come from? Are they just making them up? Oh no,
not at all. The EAS consulting group has a video
where they talk about this, and they mention
a bunch of... recognized sources for these methods.
There's the U .S. Pharmacopeia, or USP, the Association
of Official Analytical Chemists, AOAC, the Food
Chemicals Codex, FCC, even the EPA has methods
for things like testing for contaminants. Wow,
so it's a whole science in itself, figuring out
how to test these drugs. Oh, for sure. And like
we talked about with process validation, the
testing methods themselves also need to be validated
to make sure they're reliable. This actually
came up in one of our previous seasons, too.
Right. Got to make sure the tests are actually
testing what they're supposed to test. Absolutely.
So we have these qualified people using proven
methods and properly equipped labs to test these
drugs at various stages. Then what? Well, they've
got to keep track of all those test results,
right? Lots and lots of documentation, I'm guessing.
You're getting good at this. That's Subpart J
Records and Reports. This part is all about keeping
detailed, accurate records of basically everything
that happens. So if it isn't written down, it
didn't happen? That's the mantra in the pharmaceutical
world, and they really emphasize that in the
EAS Consulting Group's videos on this topic.
These records are crucial. Not just to prove
to the FDA that they're following the rules,
but also to help them improve their processes,
to track down any problems, to basically have
a history of what happened. Okay, so what kind
of records are we talking about specifically?
Everything. They need master production records,
like a super detailed recipe for each product.
Then there are batch records, which track the
making of each specific batch of the drug. Equipment
logs track all the equipment they use, when it
was maintained, calibrated, all that. And, of
course, all those testing records, from raw materials
to in -process checks to the final product testing.
Even if someone complains about a product, that
gets recorded and investigated. Wow, sounds like
a ton of paperwork. It can be. But it's super
important. And this is a big topic in one of
our earlier deep dives, too, where we talk about
all those requirements for record keeping in
part 211. The CFR sections 211 .188A, 211 .186,
and 211 .198 lay it all out. So every step, every
little detail, it's all got to be documented.
Now, what about those situations where, say,
a drug gets returned to the manufacturer, or
maybe it needs to be salvaged? Is there a specific
part of the CFR that covers that? Yep, there's
a sub part for that too, sub part K, return and
salvage drug products. Section 211 .204 of the
CFR lays out what they need to do in those situations.
So part 211, it really does cover everything
from A to Z of making a medicine. You mentioned
earlier some other CFR parts that are relevant
too. Right, like part 314, that's for new drug
applications. Before a company can sell a new
drug in the U .S., they have to go through this
whole process and obviously following CGMP. is
a must. Then there's Part 312 for investigational
new drugs. Those are the drugs used in clinical
trials. Right. So even before a drug is approved
for sale? Exactly. And those drugs are still
expected to be made following GMP, even though
they're still being tested. Charisma actually
talks about this in the FDA CITC Day 2 transcript.
It was really interesting. And there's part 320,
which covers bioavailability and bioequivalence
studies. These studies are often done for generic
drugs to show they work the same way as the brand
name drug. And to make sure those studies are
reliable, the quality of the drugs they're testing
has to be consistent. Yeah, makes sense. Consistent
quality is key for all these studies and tests.
And then there's part 58. This was not exactly
CGMP, but it's related. It's about... good laboratory
practices, GLP, for all those non -clinical lab
studies they do before testing a drug in humans.
This actually came up in that FDA CITC Day 2
transcript too. Right, so it's not just about
how you make the drug, it's about all the testing
and research that goes into it as well. Exactly.
There are rules and guidelines for every step
of the way, from early research to the final
product on the shelf. Think of it like this.
Part 211 is the super detailed instruction manual
for the physical making of the medicine. all
these other regulations like Part 314 for new
drugs or the GLP rules, they tell you why you
have to do all that and provide a bigger context
for the whole process. Yeah, it definitely seems
like a super complex web of regulations and guidelines.
And it's not just the U .S. We've got the international
scene, too. You mentioned the International Council
for Harmonization, the ICH, before. What's their
role in all of this? The ICH is all about trying
to get everyone on the same page globally. We
talked about this a bit in a previous deep dive,
remember. They work to make sure those standards
for pharmaceutical quality are more or less the
same around the world. Right. So it doesn't matter
if a drug is made in the US, Europe, or somewhere
else. The quality should be about the same. That's
the goal. And they've created some really important
guidelines. One of the big ones is ICH Q9, which
is all about quality risk management. They basically
want companies to be proactive. to think about
what could go wrong and have plans in place to
prevent those problems from happening. So like
a what -if plan for quality. Exactly. It's about
identifying those potential risks, figuring out
how likely they are to happen and how bad they
could be, and then putting controls in place
to minimize those risks. I guess that makes sense.
You can't always predict everything, but you
can try to be prepared. Right. And ICHQ9 provides
this whole framework for doing this systematically.
using science and risk assessment tools. Some
of the tools that are commonly used, like HACCP,
that's Hazard Analysis and Critical Control Points,
and FMEA, Failure Mode and Effects Analysis,
they come up in those books you shared. Oh, okay.
So they have specific methods for figuring out
the risks and how to control them. Sounds pretty
thorough. It is. And both drug manufacturers
and regulators rely on this guidance a lot. The
ICH Q9 document goes into a lot of detail. And
there are other important ICH guidelines, too.
Oh, yeah. Like what? Like ICH Q11, which focuses
on making drug substances the active ingredient
in the medicine. This one's all about picking
the right starting materials and really controlling
those impurities that might sneak in. Impurities.
Yeah, that makes sense. You don't want anything
extra in there that could cause problems. Exactly.
And the ICH Q11 Q &A video is really helpful
for understanding all the specifics. Then you've
got guidelines like ICH Q3A, which lays out acceptable
levels of impurities in new drugs, and ICH M7,
which is specifically about mutagenic impurities,
the ones that could potentially cause cancer.
OK, so basically a whole bunch of guidelines
to make sure those drugs are super pure and safe.
Right. All of this ties back to those critical
quality attributes we talked about earlier. And
it doesn't stop there. Even the way they report
the results from clinical trials, there's a guideline
for that, ICHE3. It's all interconnected because
you need consistently good quality in the drug
they're testing for those results to be reliable.
Wow. It really is a complex web. It is. There
are even more guidelines, like ICHQ -SKITSAE
on specifications, which outlines the standards
a drug has to meet, and ICHQ5C, which is specifically
for biologics. Those are complex medicines made
from living organisms. Biologics, yeah. Those
are becoming more and more common. So all these
ICH guidelines, they're like a global set of
standards for making sure medicines are safe
and effective no matter where they're made. Exactly.
Part 2 .11 gives you the U .S. specific rules,
but medicines and their ingredients are traded
globally, right? The ICH helps ensure that a
medicine made in one country is of similar quality
to one made elsewhere, building trust and consistency
across the whole supply chain. Yeah, makes sense.
But we talked earlier about how CGMP isn't just
about following the rules. It's also about creating
a culture of quality within a company. Absolutely.
It's not just about checking boxes and filling
out paperwork. CGMP has to be a mindset, a way
of thinking for everyone in the company. They
need to understand why it matters and take responsibility
for ensuring quality. Ajaz S. Hussein, a real
expert in this area, has a great video on how
important this cultural aspect of quality is.
So it's as much about the people as it is about
the procedures, right? Totally. You can have
the most detailed procedures in the world, but
if the people aren't trained well or don't care
about quality, it all falls apart. That's why
21 CFR Part 211 is very clear about the need
for qualified, trained personnel. everyone from
the scientists to the folks on the production
line, they all play a role in making sure the
final product is safe and effective. And it's
not like those rules are set in stone, right?
CGMP, the C stands for current. So it's always
evolving. That's right. Current means you got
to keep up with the times, the science, the new
technologies, the latest regulations. This was
actually something we discussed in past season
two. Continuous improvement. That's a big part
of CGMP. So, like, always striving to do things
better. Exactly. And that often involves what
they call KPA, corrective and preventive actions.
Whenever they find a problem or something goes
wrong, they don't just fix it, they try to figure
out how to prevent it from happening again. Okay,
so learning from mistakes and making changes
to improve things. There's a book by Rodriguez
Perez on Kapila. And the FDA did a whole workshop
on their Office of Surveillance and Inspection
Systems, OSES, that also talked about how important
CAPA is. Now, think about all those companies
that supply the raw materials, the containers,
all that stuff. There are even companies that
do testing for other companies, like contract
labs. They're all part of the picture, too, right?
Oh, yeah. They all play a role in making sure
the final drug is good. Exactly. And making sure
your suppliers are good is a big deal. That means
carefully picking and qualifying those contract
labs, making sure they meet all the standards.
The EAS Consulting Group did a video on contract
labs. And there's also a book called the Supplier
Management Handbook by Bossert that goes into
all the nitty gritty of this. So it really is
a team effort. Everyone in the supply chain has
to be on board with this quality thing. Now,
how does the FDA actually make sure all these
companies are following the rules? They inspect
them, right? That's the main way. The FDA sends
inspectors to those manufacturing facilities,
both in the U .S. and overseas, to make sure
they're following CGMP. Devon Edwards talks about
this in one of his videos and is also mentioned
in the FDA CITC Day 3 transcript. So what are
those inspectors looking for? They're checking
if the facilities are up to par, if the equipment
is maintained properly, if they're controlling
those materials and ingredients correctly, if
they're sticking to those validated processes,
if the packaging and labeling is accurate, if
the labs are doing things right, if the records
are complete and correct, if the whole company
has that quality mindset. They're basically looking
for proof that everything's being done right
to ensure the quality of those drugs. And if
they find problems, what happens? Well, there
are a few different outcomes. The best one is
NAI, no action indicated, meaning they didn't
find any big issues. Then there's VAI, voluntary
action indicated. This means they found some
minor things that need to be fixed, but it's
not serious enough to take regulatory action.
OK, so like a warning, but not a full -blown
penalty? Exactly. But then there's OAI, official
action indicated. This is when they find serious
problems, things that don't comply with CGMP.
That's when things can get a bit more serious.
OAI, that sounds bad. Yeah, that's not good.
The understanding FDA inspections video explains
all these different classifications. If a facility
gets hit with an OAI, the FDA can issue a warning
letter. Oh, so it's like getting a formal reprimand.
Yeah, it's official. They list out all the violations
and the company has to fix them. If they don't,
things can escalate. Escalate, like what could
happen? Well, they could face a recall of their
product. They could even be banned from importing
those products into the US. And in the worst
cases, they could face legal action, fines, even
criminal charges, especially if it seems like
they intentionally violated the rules. Devon
Edwards talks about all this in his video. So
it's not something to be taken lightly. Definitely
not. And during the inspection, the FDA will
typically document their observations on a form
called Form 4A3. The company has to respond to
those observations and, more importantly, actually
take action to correct those problems. It's all
about accountability. Right. Now, there is also
mention of something called the FDA's Bioresearch
Monitoring Program. Right, the BIMO program.
This one's all about clinical trials, making
sure the data from those trials is reliable and
accurate. This is super important because this
data is what the FDA uses to decide whether to
approve a new drug or not. Yeah, I guess if the
data is bad, the FDA might make the wrong decision.
Exactly. Kara Alaro actually presented on this
program in the FDA CITC Day 3 transcript. It's
worth checking out if you want to learn more.
OK, so they inspect those trials to make sure
everything's done right. And I think there was
something about remote assessments, too. Yeah,
remote assessments. That's something newer the
FDA is doing. They're basically like virtual
inspections where they might review documents
remotely. Oh, interesting. So not always having
to send inspectors to a physical location. Exactly.
Yeah. Emily Geva actually talked about this in
the FDA CITC day three transcript. She said it's
becoming a more important tool for the FDA. Sounds
like the FDA has got to be flexible and adapt
to how things are changing. For sure. They're
constantly evolving. OK. To wrap things up, what
are the big consequences for a company that doesn't
follow CGMP? It can be pretty bad. We talked
about warning letters, product recalls, legal
action, all that. It can cost them a lot of money.
damage their reputation, and in the worst cases,
people could get hurt if a drug isn't made properly.
It also erodes trust in the whole pharmaceutical
industry, which is not good for anyone. Yeah,
definitely a lot at stake. OK, let's recap the
key takeaways for our listeners. What's the big
picture here? The most important thing to remember
is that quality has to be baked into every step
of making a medicine, from designing the facility
to picking ingredients to making the drug, testing
it, documenting everything. Quality is non -negotiable
and of course you have to follow all those rules
in the CFR and those ICH guidelines But beyond
all that it's about having a real culture of
quality within a company, where everyone understands
their role in making safe and effective medicines.
And it really hits home when you look at past
mistakes, like the thalidomide tragedy. That
was a huge wake -up call. It was. The book Wonder
Drug tells the story of thalidomide, and it's
a stark reminder of what can happen when we don't
have those rigorous quality controls. The birth
defects caused by that drug, they show the real
-world consequences, the human cost of not taking
quality seriously. Really makes you think. But
there are also positive examples, right? Like
that company we talked about in a previous deep
dive, the one that aced an FDA inspection because
their documentation was so thorough. Absolutely.
Their meticulous record keeping showed the FDA
they were really committed to quality. It shows
that these aren't just theoretical rules. They
have a real impact on preventing harm and making
sure people have access to safe and effective
medicines. For sure. So to our listeners, if
you're interested in learning more, check out
the CFR, the ICH guidelines. You can even dive
into the history of GMP. It's pretty fascinating
to see how it evolved. And here's something to
ponder. Medicines are made and sold all over
the world now. How can we improve global collaboration,
make those CGMP standards even more consistent
across countries to make sure every medicine
everywhere is safe and effective? That's a big
question. And finding solutions could have a
huge impact on global health. Yeah, definitely
something to think about.